Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATG7 | O95352 | 11/20 | 0.71 |
| ▸ | ADK | P55263 | 7/20 | 0.65 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.65 |
| ▸ | CDK1 | P06493 | 2/20 | 0.65 |
| ▸ | ROS1 | P08922 | 2/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.65 |
| ▸ | CDK2 | P24941 | 2/20 | 0.65 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.65 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.65 |
| ▸ | CLK2 | P49760 | 2/20 | 0.65 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.65 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.65 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.65 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.65 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.65 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533179 | 1.00 | ATG7 (0.71) | ATG7ADKDYRK3CDK1ROS1 | |
| SCHEMBL13337873 | 1.00 | ATG7 (0.71) | ATG7ADKDYRK3CDK1ROS1 | |
| SCHEMBL20141774 | 1.00 | ATG7 (0.71) | ATG7ADKDYRK3CDK1ROS1 | |
| SCHEMBL20142486 | 1.00 | ATG7 (0.71) | ATG7ADKDYRK3CDK1ROS1 | |
| SCHEMBL14038325 | 0.87 | ATG7 (0.57) | ATG7 | |
| SCHEMBL2908818 | 0.86 | ATG7 (0.55) | ATG7ADKDYRK3CDK1ROS1 | |
| SCHEMBL12762314 | 0.85 | ATG7 (0.54) | ATG7 | |
| SCHEMBL20142123 | 0.84 | ATG7 (0.74) | ATG7 | |
| SCHEMBL20141551 | 0.84 | ATG7 (0.74) | ATG7 | |
| SCHEMBL22758711 | 0.84 | ATG7 (1.00) | ATG7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975256-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1975256-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH BIOSCIENCES INC (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-1261616-B1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1261616-B1 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENCES INC (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-7751982-B2 | TM leveling methods | ELITECH HOLDING B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-7715989-B2 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | ELITECH HOLDING B.V. (NL) | 2010-05-11 | — | — | US | disclosed |
| EP-1995330-A1 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1995330-A1 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1975256-A1 | Modified oligonucleotides for mismatch discrimination | Epoch Biosciences, Inc. (US) | 2008-10-01 | — | — | EP | disclosed |
| US-20060003349-A1 | Tm leveling compositions | EPOCH BIOSCIENCES, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-6949367-B1 | Modified oligonucleotides for mismatch discrimination | EPOCH PHARMACEUTICALS, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1537488-A2 | SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) | Epoch Biosciences, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050075491-A1 | TM leveling methods | EPOCH BIOSCIENCES, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| US-6683173-B2 | CONJUGATING OLIGONUCLEOTIDE WITH 3-SUBSTITUTED PYRAZOLO(3,4-D)PYRIMIDINES AND/OR 5-SUBSTITUTED PYRIMIDINE MINOR GROOVE BINDER | EPOCH BIOSCIENCES, INC. | 2004-01-27 | — | — | US | disclosed |
| US-20030235822-A1 | Systems and methods for predicting oligonucleotide melting temperature (TmS) | EPOCH BIOSCIENCES, INC. | 2003-12-25 | — | — | US | disclosed |
| WO-2003107144-A2 | SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) | EPOCH BIOSCIENCES, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030224359-A1 | TMLEVELING METHODS | EPOCH BIOSCIENCES, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1261616-A2 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | Epoch Biosciences, Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001064958-A2 | MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION | EPOCH BIOSCIENECS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003349-A1 | Tm leveling compositions | RNGTT, TYMS, NT5C3B | ATG7 4221/4885ADK 890/4885DYRK3 4207/4885 |
| US-20050075491-A1 | TM leveling methods | RNGTT, TYMS, NT5C3B | ATG7 4004/4885ADK 1165/4885DYRK3 4161/4885 |
| US-20030224359-A1 | TMLEVELING METHODS | PTBP3, RNGTT, DTYMK | ATG7 4775/4885ADK 1689/4885DYRK3 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.